The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BMRN | -21.47% | -30.9% | -7.12% | +301% |
| S&P | +13.96% | +91.24% | +13.85% | +404% |
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Although the company recorded higher sales overall, it's decided to divest one of its products.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $786.77M | 6.0% |
| Gross Profit | $641.84M | 16.9% |
| Gross Margin | 81.58% | 7.6% |
| Market Cap | $10.40B | -22.3% |
| Market Cap / Employee | $3.42M | 0.0% |
| Employees | 3K | -10.6% |
| Net Income | -$30.74M | -129.0% |
| EBITDA | $203.40M | 17.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.25B | 85.1% |
| Accounts Receivable | $790.27M | 1.6% |
| Inventory | 1.4K | 17.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $596.66M | 0.3% |
| Short Term Debt | $14.52M | -6.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 7.20% | 2.5% |
| Return On Invested Capital | 5.50% | 1.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $340.24M | 67.6% |
| Operating Free Cash Flow | $368.69M | 66.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 29.89 | 26.23 | 16.28 | 20.29 | -52.05% |
| Price to Book | 2.31 | 2.38 | 1.82 | 1.73 | -31.84% |
| Price to Sales | 4.55 | 4.75 | 3.56 | 3.37 | -33.17% |
| Price to Tangible Book Value | 2.53 | 2.63 | 1.97 | 1.86 | -32.94% |
| Price to Free Cash Flow TTM | 26.51 | 22.25 | 15.59 | 12.50 | -71.15% |
| Enterprise Value to EBITDA | 76.88 | 52.28 | 31.29 | 46.87 | -40.08% |
| Free Cash Flow Yield | 3.8% | 4.5% | 6.4% | 8.0% | 246.60% |
| Return on Equity | 8.0% | 9.6% | 11.6% | 9.1% | 45.15% |
| Total Debt | $649.47M | $609.82M | $611.88M | $611.19M | 0.17% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
